HBIO

Business Context and Reporting Period

Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2006
Business Overview: The Company manufactures and distributes apparatus, instruments, and consumables for life science research. Operations are divided into the Apparatus and Instrumentation Business segment (continuing operations) and the Capital Equipment Business segment (discontinued operations, held for sale). The Company is actively pursuing a strategy of organic growth and "tuck-under" acquisitions while preparing to divest the Capital Equipment segment.

Key Financial Metrics

Note: Net income figures include losses from discontinued operations. Continuing operations generated net income of $1.3 million for the quarter and $4.7 million for the nine-month period.

Material Changes vs. Prior Period

• Revenue Growth: Revenues from continuing operations increased 10.3% ($1.8M) for the quarter and 9.9% ($4.9M) for the nine months compared to the prior year. Growth was driven by core physiology and cell biology equipment, new spectrophotometer products, and the acquisition of Anthos product lines.
• Discontinued Operations: The Capital Equipment Business segment reported a net loss of $1.5M for the quarter and $4.6M for the nine months. This is a significant improvement over the $26.8M loss in the prior year's nine-month period, which included massive goodwill and asset impairment charges ($17.4M total in 2005).
• Expense Increases: General and administrative expenses rose 28.6% for the quarter and 15.1% for the nine months. This increase is primarily attributed to the adoption of SFAS 123(R), resulting in $0.5M (quarter) and $1.3M (nine months) of stock-based compensation expense, alongside increased bonus expenses.
• Debt Reduction: The Company repaid $5.5M on its revolving credit facility during the nine months ended September 30, 2006, reducing the outstanding balance from $8.5M to $3.0M.

Guidance, Outlook, and Risks

• Divestiture Strategy: Management anticipates selling the Capital Equipment Business segment in Q4 2006 or Q1 2007. Proceeds are intended for debt repayment or further acquisitions. However, the sale requires lender consent; failure to obtain consent could trigger a default under the credit facility.
• Capital Resources: The Company has a $20M revolving credit facility expiring January 1, 2007. As of September 30, 2006, $17.0M was available, though covenants limited borrowing capacity to approximately $15.8M. Management expects current cash and debt capacity to support operations for 12 months and beyond.
• Acquisitions: The Company acquired assets from Anthos Labtec Instruments GmbH for $1.1M in June 2006. Future growth relies on "tuck-under" acquisitions, which may require additional capital raising.
• Risks: Key risks include the inability to complete the divestiture on attractive terms, foreign currency fluctuations (significant exposure to GBP and Euro), and the potential need to raise additional capital which could dilute shareholders.

Investor Verification Checklist

• Divestiture Timeline: Verify the status of the Capital Equipment Business sale and whether lender consent has been secured to avoid credit facility default.
• Stock-Based Compensation Impact: Assess the long-term impact of SFAS 123(R) adoption on future operating margins, as this added significant non-cash expense in 2006.
• Debt Covenants: Review the specific financial covenants (income, debt coverage, working capital) in the credit facility to ensure continued compliance, especially given the reduction in cash reserves.
• Discontinued Operations Impairment: Confirm if further impairment charges are expected for the Capital Equipment segment prior to its sale, as fair value was re-evaluated in Q3 2006.
• Foreign Exchange Exposure: Monitor the strength of the U.S. dollar against the Euro and British Pound, as a stronger dollar negatively impacts reported revenue and earnings from international operations.